EGFR and colorectal carcinoma: The mutation of KRAS, a member of the rat sarcoma virus gene family of downstream genes of EGFR, devotes most part of mutated genes in the EGFR signaling pathway (35%–45% of all CRC), which strongly correlates with poorer outcomes in patients with CRC [12].